Product failure / C-029
Contamination, mislabelling and what is in the vial
A label can fail in several ways. Identity, quantity, sterility, endotoxin, stability and batch provenance each need their own evidence.
Contamination and mislabelling are different product failures. A vial may contain the wrong molecule, the wrong quantity, an undeclared ingredient, microbial contamination, endotoxin or degraded material. A genuine laboratory result can still fail to describe the vial if the batch link is missing.
Failure type and the evidence that detects it
| Failure | Evidence needed | What a purity percentage cannot do |
|---|---|---|
| Wrong molecule | Identity evidence such as suitable mass spectrometry, with interpretation and reference. | It cannot name a peak merely because the chromatogram looks clean. |
| Wrong quantity | A validated quantitative assay with units, calibration and uncertainty. | Area purity does not establish milligrams in the vial. |
| Microbial contamination | Sterility or bioburden testing appropriate to the product and intended claim. | Chemical identity and purity do not detect viable organisms. |
| Endotoxin | A separate bacterial endotoxin test with a stated limit and method. | A sterile result does not automatically establish endotoxin status. |
| Degradation | Stability-indicating methods, storage records and time-linked testing. | A result from manufacture cannot prove later transport conditions. |
| Document mismatch | Matching product, batch, date, issuer and verification route. | A genuine document for another sample says nothing about this vial. |
Research record added 6 September 2026. Read the GLP-1 laboratory impurity-study record for the sample and measurement limits that apply to this product-quality research.
What the UK record establishes
UK regulator notices document concrete failures in the wider injectable and weight-loss market. In February 2026, the MHRA identified falsified Mounjaro pens carrying a stated batch number. In July 2026, the MHRA warned that illegal GLP-1 products might contain a different substance or bacterial and other contamination.
These cases prove that falsification and contamination risks are real. They do not provide a prevalence estimate for every peptide vial. The correct conclusion stays tied to the named incident, product and finding.
Read the separate evidence page on counterfeit and unauthorised GLP-1-type products.
How we describe a product failure
We record the jurisdiction, product presentation, batch or identifier, finding and official source. We then map that failure to the method that could detect it. We do not turn a seizure, warning or failed sample into a market-wide percentage.
If a product does not match
Preserve useful information without delaying care
- Record the label, batch, seller, purchase date and delivery details.
- Keep packaging, receipts, screenshots and the certificate supplied.
- Do not handle used needles or damaged containers to collect evidence.
- If symptoms occurred, record the timeline and report the event.
- Report an online seller through the MHRA route when the concern is illegal supply or misrepresentation.
Questions about vial failure
What does peptide mislabelling include?
Mislabelling can include the wrong molecule, an incorrect amount, an undeclared ingredient, a false batch reference or claims unsupported by the tests shown. Each failure needs a different check.
Can HPLC purity detect bacteria or endotoxin?
No. A chromatographic purity result does not establish sterility or endotoxin status. Those attributes need separate, validated microbiological or endotoxin tests on a representative sample.
Does one failed product prove every seller product is contaminated?
No. A documented incident establishes that the named product or batch failed in the stated way. It supports the reality of the failure mode, not a prevalence claim for the whole market.
What should I do if a vial and certificate do not match?
Do not treat the certificate as evidence for that vial. Keep the packaging and transaction records, avoid unsafe handling, and use the relevant MHRA seller or Yellow Card reporting route.
Primary sources
- MHRA Safety Roundup: falsified MounjaroAccessed 7 August 2026
- MHRA: no summer shortcut for safe weight lossAccessed 7 August 2026
- MHRA Yellow Card reporting guidanceAccessed 7 August 2026
- What peptide tests can proveAccessed 7 August 2026
Enforcement case study
A documented label-to-test mismatch
US prosecutors said many Paradigm products labelled as SARMs contained testosterone. The published finding concerns the SARM products, not every peptide vial sold by the business, and it demonstrates why product categories and tested samples must remain precise.
Editorial experience
From our work: how we checked this page
For topical-map item C-029, Contamination, mislabelling and what is in the vial was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 3 unique external sources and 7 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Research reference checked and reviewed · 6 September 2026. Scientific review: Eleni Kiromitis. Clinical review: Dr Stavroula Nikitopoulou. The existing evidence verdict is unchanged; earlier sources retain their own check dates.